Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101035 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,198
- Enrollment target
NCT01101035 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 6,198 participants.
The verdict
NCT01101035, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,198 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
Interventions
- DRUG Allopurinol
- DRUG Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,198 participants |
| Start Date | 2010-04-23 |
| Est. Completion | 2017-07-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01101035
The ClinicalTrials.gov registry entry for NCT01101035 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allopurinol is the first listed.
NCT01101035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01101035 about?
NCT01101035 is a clinical study titled "Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)". The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
What is the current status of trial NCT01101035?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,198 participants. The study started on 2010-04-23. Estimated completion is 2017-07-18.
What interventions are being tested in trial NCT01101035?
The interventions under investigation include: Allopurinol (DRUG), Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01101035?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.